Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Suceagu – page 24

447 clinical trials in Suceagu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Suceagu at a glance
447
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

447 trials in Suceagu

Open in trial search

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

HIV infection

Not recruiting

Study of Weekly Oral GS-1720 and GS-4182 for Untreated HIV-1 Patients

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Inhibrx Biosciences Inc.

Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Daiichi Sankyo Inc.

Comparison of two doses of cabozantinib (60 mg vs 140 mg) in patients with progressive metastatic medullary thyroid cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Celltrion Inc.

Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Lupus nephritis

Not recruiting

Study on the Effects of Ianalumab with Standard Therapy for Patients with Active Lupus Nephritis

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study of Zolbetuximab and CAPOX for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Suceagu

What the registry says about research in the country

01 Female Urogenital Diseases and Pregnancy Complications

In Suceagu, clinical research in female urogenital diseases is focused on improving care for stress urinary incontinence. The trials are looking at whether new treatment approaches can better reduce symptoms and support daily comfort for women living with this condition.

  • Stress urinary incontinence
  • Female urogenital health
  • Symptom control and quality of life
  • Evaluating a new therapy approach

This area reflects a practical effort to find more effective options for a common and often disruptive condition.

02 Neoplasms

Cancer research in this city includes studies in non-small cell lung cancer, with attention on patients who have HER2 mutations. The work is aimed at determining whether a targeted treatment can improve outcomes compared with standard care after surgery.

  • Non-small cell lung cancer
  • HER2-mutated tumors
  • Post-surgical cancer care
  • Testing treatment effectiveness

This field highlights efforts to advance more precise cancer treatment strategies and strengthen long-term disease control.

03 Metabolic and Urologic Symptom Research

Another active focus combines obesity or overweight with urinary incontinence, reflecting interest in how weight-related health issues may affect urinary symptoms. The research is designed to see whether a new therapy can better improve patient-reported outcomes.

  • Obesity and overweight
  • Urinary incontinence
  • Women’s health
  • Improving symptom outcomes

These studies bring together metabolic and urologic care in a way that may help guide more personalized treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.